4//SEC Filing
ABERCROMBIE GEORGE B 4
Accession 0001127602-22-005295
CIK 0000882796other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 4:25 PM ET
Size
8.6 KB
Accession
0001127602-22-005295
Insider Transaction Report
Form 4
ABERCROMBIE GEORGE B
Director
Transactions
- Exercise/Conversion
Common Stock
2022-02-15$3.32/sh+5,000$16,600→ 5,000 total - Sale
Common Stock
2022-02-15$18.50/sh−5,000$92,500→ 0 total - Exercise/Conversion
Automatic Stock Option Grant
2022-02-15−5,000→ 5,000 totalExercise: $3.32Exp: 2022-05-23→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F3]The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001485939
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 4:25 PM ET
- Size
- 8.6 KB